HomeHiltonol BackgroundClinical Trials

Hiltonol® plus Dendritic Cell Vaccine for Recurrent Glioblastoma
April, 2007. Oncovir is pleased to announce the opening of a new clinical trial of Hiltonol® plus a dendritic cell vaccine targeting specific brain tumor antigens in patients with recurrent glioblastoma. The study is being conducted by Dr. Hideho Okada at the University of Pittsburgh Medical Center.

Hiltonol® (Poly-ICLC) plus Temodar® Treatment of Glioblastoma, A Multicenter Clinical Trial
January, 2006. Oncovir is pleased to announce the opening of a new multicenter clinical trial to be conducted in collaboration with the prestigious NABTT consortium. Patients with newly diagnosed glioblastoma will be treated with a combination of Hiltonol (Poly-ICLC) and Temodar® chemotherapy. 

Hiltonol™ (Poly-ICLC) Treatment of Brain Tumors
April, 2003. Oncovir is cosponsoring two multicenter phase II clinical trials of treatment with its experimental product, Hiltonol™ (poly-ICLC) for patients with malignant brain tumors. The trials are being conducted by the prestigious North American Brain Tumor Consortium (NABTC). 

Hiltonol™(Poly-ICLC) Treatment in a Smallpox Model
In a presentation at the International Conference on Antiviral Research in Savannah, Dr. Samuel Baron of Galveston reported marked protection by Hiltonol™ in an otherwise lethal model of disseminated vaccinia poxvirus infection in mice. A single injection of Hiltonol™ provided 80 to 100% protection against mortality due to disseminated virus for as long as 8 days, and a greater than 100-fold inhibition in organ viral load. The vaccinia virus is also the basis of the current smallpox live-virus vaccines, but treatment with Hiltonol™ did not prevent the development of long term immunity to vaccination. The authors infer that treatment with a low, non-toxic dose of Hiltonol™ at the same time as vaccination of humans may provide immediate protection against smallpox and may reduce vaccine complications, while not inhibiting the immune response to vaccination.

Enter supporting content here